Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-08T08:15:55.367Z Has data issue: false hasContentIssue false

Paliperidone palmitate versus other antipsychotics

Published online by Cambridge University Press:  23 March 2020

P. Hervías Higueras*
Affiliation:
Hospital Dr. R. Lafora, Psiquiatría, Madrid, Spain
L. Maroto Martín
Affiliation:
Hospital Dr. R. Lafora, Psiquiatría, Madrid, Spain
S. Raffo Moncloa
Affiliation:
Hospital Dr. R. Lafora, Psiquiatría, Madrid, Spain
M. Leonor del Pozo
Affiliation:
Hospital Dr. R. Lafora, UHB Psiquiatría, Madrid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The aim of the study was to describe the psychopharmacological treatments received by inpatients diagnosed with spectrum disorders schizophrenia and other psychotic disorders in Dr. Rodriguez Lafora Hospital. It is an observational, descriptive and retrospective study. We collected information about patients aged 18 to 64 who were hospitalized during the month of January of 2015 in the acute psychiatric hospitalization by Selene software. We reviewed treatments and number of psychiatric re-hospitalization six months later and we analyzed the results by SPSS software. From a sample of 51 inpatients, 15 of them were diagnosed with disorders of the spectrum of schizophrenia and other psychotic disorders. Of the patients, 13.3% was treated with haloperidol, 26.7% with olanzapine, 26.7% with risperidone although it was modified by paliperidone in mental health center, 6.7% with quetiapine, 6.7% with amisulpride, 13.3% with oral paliperidone and 13.3% patients with intramuscular paliperidone. Of these, 40% are readmitted to hospital. Patients were readmitted due to ineffectiveness and adverse effects of haloperidol, olanzapine, risperidone. 73.3% of inpatients were treated with monotherapy. Of the patients, 26.7% were treated with polytherapy, who received olanzapine, risperidone and amisulpride. It would be important to use psychoactive substances that allow monotherapy to reduce adverse effects and psychiatric re-hospitalization.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1018
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.